Real-time Influenza Vaccine Surveillance
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01233388|
Recruitment Status : Completed
First Posted : November 3, 2010
Last Update Posted : June 12, 2012
|Condition or disease||Intervention/treatment|
|Vaccine Safety||Other: Text message surveillance|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||400 participants|
|Official Title:||Real-time Influenza Vaccine Surveillance: FLUNET|
|Study Start Date :||November 2010|
|Primary Completion Date :||May 2012|
|Study Completion Date :||May 2012|
Text message surveillance
enroll for text message surveillance
Other: Text message surveillance
Text message surveillance for vaccine adverse events
Other Name: Flunet
- Number of participants who report a health symptom within 6 weeks of vaccination [ Time Frame: 6 weeks ]As this is a pilot study, we want to first determine if people will report health problems. Therefore, we will assess the number of participants who report a health problem within 6 weeks of vaccination.
- Sensitivity of the patient reporting compared to medical record [ Time Frame: 6 weeks ]We will compare information provided by participants for moderate-to-severe health problems with the medical record to determine sensitivity of reporting.
- Specificity of the patient reporting compared to medical record [ Time Frame: 6 weeks ]We will compare information provided by participants for moderate-to-severe health problems with the medical record to determine specificity of reporting.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01233388
|United States, New York|
|Columbia University Medical Center|
|New York, New York, United States, 10032|
|Principal Investigator:||Philip LaRussa, MD||Columbia University|
|Principal Investigator:||Melissa Stockwell, MD MPH||Columbia University|